TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17714557

Group type: EXPERIMENTAL
Intervention: Preoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Preoperative proton pump inhibitor‐based triple therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (Billroth I)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (Billroth II)
Number of subjects: 138
Study: 16459898

Group type: EXPERIMENTAL
Intervention: Masking of T2 by a trailing item
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silence following T2 instead of a trailing item
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T2 as the last presented stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed masking of T2
Number of subjects: 0
Study: 12414333

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 6
Study: 10325830

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% sevoflurane
Number of subjects: 0
Study: 8568487

Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normotensive, similar age)
Number of subjects: 16
Study: 2009056

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (specific combinations not detailed)
Number of subjects: 1392

Group type: COMPARATOR
Intervention: No systemic therapy (control group)
Number of subjects: 1392
Study: 7272159

Group type: EXPERIMENTAL
Intervention: Twice-daily flurbiprofen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Four times daily flurbiprofen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Twice-daily flurbiprofen without an evening dose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 17
Study: 31376438

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Approach food bias via SRCT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Implicit attitudes to food cues via IAT
Number of subjects: 42
Study: 30029461

Group type: EXPERIMENTAL
Intervention: 8 g/day polydextrose
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 12 g/day polydextrose
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 26779838

Group type: EXPERIMENTAL
Intervention: Web-based interactive breastfeeding monitoring system
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard hospital protocol (Control)
Number of subjects: 141
Study: 24922494

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg) over 40 minutes
Number of subjects: 108
Study: 21761341

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) treatment
Number of subjects: 82
Study: 19281871

Group type: EXPERIMENTAL
Intervention: staging acupuncture group
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: staging acupuncture and moxibustion group
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: staging electro-acupuncture group
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: staging acupuncture along yangming musculature group
Number of subjects: 900

Group type: COMPARATOR
Intervention: non-staging acupuncture control group
Number of subjects: 900
Study: 17201538

Group type: EXPERIMENTAL
Intervention: Self-expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of choice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value of expression
Number of subjects: 0
Study: 15547086

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11182190

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid plus conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Number of subjects: 64
Study: 9337494

Group type: EXPERIMENTAL
Intervention: SST with parent‐mediated generalization (SST‐PG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Child‐only SST
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study: 7631093

Group type: EXPERIMENTAL
Intervention: Medical treatment with L-Dopa and anticholinergics
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thalamo-subthalamotomies plus medical treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Autologous adrenal medullary transplantation plus medical treatment
Number of subjects: 3
Study: 3283921

Group type: EXPERIMENTAL
Intervention: 1 g aztreonam as a single intramuscular injection
Number of subjects: 236

Group type: COMPARATOR
Intervention: Procaine penicillin plus probenecid
Number of subjects: 236
Study: 29747091

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 27158085

Group type: EXPERIMENTAL
Intervention: Ketoprofen gel (2 g of 2.5% ketoprofen gel)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Number of subjects: 140
Study: 24943961

Group type: EXPERIMENTAL
Intervention: Weekly azithromycin for 3 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 22619063

Group type: EXPERIMENTAL
Intervention: Boceprevir with peginterferon/ribavirin
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Week 12 HCV RNA cutoff of ≥ 100 IU/mL stopping rule
Number of subjects: 681

Group type: COMPARATOR
Intervention: Week 12 HCV RNA levels between 9.3 IU/mL and 25 IU/mL
Number of subjects: 681

Group type: COMPARATOR
Intervention: Week 12 HCV RNA level of 148 IU/mL
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Combination of stopping rules (HCV RNA level ≥ 100 IU/mL at week 12 and detectable HCV RNA at week 24)
Number of subjects: 681
Study: 20529318

Group type: EXPERIMENTAL
Intervention: Outdoor recreational physical activity (PA)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Factors influencing outdoor recreational PA
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Factors influencing outdoor recreational PA among women
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Age influence on outdoor recreational PA
Number of subjects: 999
Study: 18996870

Group type: EXPERIMENTAL
Intervention: UNIMMAP (UNICEF/WHO/UNU international multiple micronutrient preparation)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: UNIMMAP
Number of subjects: 1426
Study: 16970099

Group type: EXPERIMENTAL
Intervention: Shufei Granule (SG) 10 g 3 times a day orally, in addition to control treatment.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fleroxacin 0.2 g twice per day by intravenous dripping and diprophylline 0.2 g 3 times per day orally (Control group).
Number of subjects: 100
Study: 12913678

Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-oxidant and micronutrient therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood glucose regulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhancement of gut motility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemia/reperfusion injury management
Number of subjects: 0
Study: 10549446

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 200

Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 200
Study: 8694015

Group type: EXPERIMENTAL
Intervention: Fungal oil (0.8 g AA, 0.6 g DHA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fungal oil (2.2 g AA, 1.7 g DHA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fungal oil (3.6 g AA, 2.9 g DHA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fungal oil (0 g AA, 0 g DHA)
Number of subjects: 32
Study: 1859514

Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 3330

Group type: COMPARATOR
Intervention: Digitalis
Number of subjects: 3330

Group type: EXPERIMENTAL
Intervention: Ibopamine and Digitalis (combined)
Number of subjects: 3330
Study: 6601789

Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low frequency TENS (2 Hz)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation
Number of subjects: 62
Study: 31752813

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse + adhesive (ER)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Selective enamel etch + adhesive (SEE)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (SE)
Number of subjects: 150
Study: 30384375

Group type: EXPERIMENTAL
Intervention: Palosuran 500 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27260129

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg and tolterodine ER 4 mg per day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and tolterodine ER 4 mg per day
Number of subjects: 220
Study: 24839034

Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: 940 nm diode laser
Number of subjects: 20
Study: 22443848

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 331
Study: 19531946

Group type: EXPERIMENTAL
Intervention: MPM0‐III
Number of subjects: 124171

Group type: EXPERIMENTAL
Intervention: Subgroup models
Number of subjects: 124171
Study: 17654694

Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg t.i.d. with sarizotan 5 mg b.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Levodopa 100 mg t.i.d. without sarizotan
Number of subjects: 16
Study: 15342853

Group type: EXPERIMENTAL
Intervention: Induced hypothermia after inpatient pediatric cardiac arrest
Number of subjects: 76
Study: 11252121

Group type: EXPERIMENTAL
Intervention: Tube feeding placement during index hospitalization
Number of subjects: 99

Group type: COMPARATOR
Intervention: No tube feeding (31% left without a feeding tube)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Admitting diagnosis of infection
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 99
Study: 15512184

Group type: EXPERIMENTAL
Intervention: Alora (0.1 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Estraderm (0.1 mg/day)
Number of subjects: 24
Study: 8087189

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 10 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Ned) 4 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2679978

Group type: EXPERIMENTAL
Intervention: Dobutamine 7 micrograms.kg-1.min-1 (group D)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 93
Study: 1252881

Group type: EXPERIMENTAL
Intervention: Computer-held medical records
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard hospital notes
Number of subjects: 278
Study: 29325753

Group type: EXPERIMENTAL
Intervention: Induced hypothermia (target 32‐34°C) for 24 hours followed by normothermia (36‐38°C) for 48 hours
Number of subjects: 436

Group type: COMPARATOR
Intervention: Routine thermal management
Number of subjects: 436
Study: 26821045

Group type: EXPERIMENTAL
Intervention: Gastric load of 700 kcal/500 mL
Number of subjects: 37

Group type: COMPARATOR
Intervention: Gastric load of 100 kcal/500 mL
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral exposure duration of 8 min
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral exposure duration of 1 min
Number of subjects: 37
Study: 24837113

Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water, complemented with the use of hand sanitizer (Experimental Group)
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Usual handwashing procedure (Control Group)
Number of subjects: 1609
Study: 21825081

Group type: EXPERIMENTAL
Intervention: Inflammation-based management strategy (sputum eosinophils)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Symptom-based management strategy
Number of subjects: 55
Study: 21031289

Group type: EXPERIMENTAL
Intervention: Home-based specific stabilizing exercises targeting local trunk muscles
Number of subjects: 88

Group type: COMPARATOR
Intervention: Single telephone contact with a physiotherapist (Control)
Number of subjects: 88
Study: 17118686

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 microg, two inhalations twice daily
Number of subjects: 673

Group type: COMPARATOR
Intervention: Budesonide/formoterol DPI 160/4.5 microg, two inhalations twice daily
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI
Number of subjects: 673

Group type: COMPARATOR
Intervention: Budesonide/formoterol DPI
Number of subjects: 673
Study: 16544967

Group type: EXPERIMENTAL
Intervention: Minoxidil (5 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12568835

Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 40
Study: 11007222

Group type: EXPERIMENTAL
Intervention: Triple therapy (DeNoltab 120 mg, amoxycillin 500 mg, and metronidazole 300 mg four times daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: DeNoltab 120 mg four times daily alone
Number of subjects: 120
Study: 8632537

Group type: EXPERIMENTAL
Intervention: Combined neoadjuvant intravesical chemotherapy and local hyperthermia (group 1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (group 2)
Number of subjects: 52
Study: 1363892

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy before surgery for stage IIIA NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs (Navelbine, taxol, campthotecine) for NSCLC chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose intensity improvement with growth factors for SCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractionation of therapy for SCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation for SCLC
Number of subjects: 0
Study: 6302649

Group type: EXPERIMENTAL
Intervention: Sutureless skin closure using Op‐Site skin closures
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 51
Study: 31138728

Group type: EXPERIMENTAL
Intervention: Elastic tubing resistance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Weight-machine training (conventional resistance group)
Number of subjects: 28
Study: 28842997

Group type: EXPERIMENTAL
Intervention: Ombitasvir and paritaprevir/ritonavir without ribavirin for 12 weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Ombitasvir and paritaprevir/ritonavir with ribavirin for 16 weeks
Number of subjects: 204
Study: 26098737

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: CPT-Cognitive Only (CPT-C)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Written Accounts (WA)
Number of subjects: 321
Study: 25155608

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both EFV and LPV/r
Number of subjects: 0
Study: 22289222

Group type: EXPERIMENTAL
Intervention: Insemination at 56 h after CIDR removal
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Insemination at 72 h after CIDR removal
Number of subjects: 1098
Study: 20732608

Group type: EXPERIMENTAL
Intervention: Ergonomically designed facemask
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard facemask
Number of subjects: 32
Study: 17524796

Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Exercise-placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 16272048

Group type: EXPERIMENTAL
Intervention: ECCE (conventional extracapsular cataract surgery)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: SICS (manual small‐incision cataract surgery)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: PE (phacoemulsification)
Number of subjects: 186
Study: 11863478

Group type: EXPERIMENTAL
Intervention: Transferrin receptor-ferritin index (TR-F index)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine blood tests (serum iron, ferritin, and transferrin saturation levels)
Number of subjects: 63
Study: 9988416

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonically guided multifetal pregnancy reduction using a modified technique (no KCl, aspirating embryonic parts)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonreduced twins
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonreduced triplets and quadruplets
Number of subjects: 75
Study: 7486096

Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% glucose
Number of subjects: 270

Group type: COMPARATOR
Intervention: 0.5% bupivacaine in 8.5% glucose
Number of subjects: 270
Study: 2268867

Group type: EXPERIMENTAL
Intervention: 500 mg of cefuroxime axetil orally (250 mg q12h)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 1,000 mg of cefuroxime axetil orally (500 mg q12h)
Number of subjects: 185

Group type: COMPARATOR
Intervention: 1,500 mg of cefaclor orally (500 mg q8h)
Number of subjects: 185
Study: 6108248

Group type: EXPERIMENTAL
Intervention: Spring-loaded clip
Number of subjects: 299

Group type: COMPARATOR
Intervention: Tubal ring
Number of subjects: 299
Study: 30925126

Group type: EXPERIMENTAL
Intervention: Personally tailored, automated telephone symptom management intervention
Number of subjects: 556

Group type: COMPARATOR
Intervention: Usual care enhanced with a nontailored newsletter about symptom management
Number of subjects: 556
Study: 27527354

Group type: EXPERIMENTAL
Intervention: DPBN-8 Gy (dose range between 6 and 10 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ConvRT-8 Gy (conventionally planned radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DPBN-16 Gy (dose range between 14 and 18 Gy)
Number of subjects: 0
Study: 25591433

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ringer lactate solution (RL) group
Number of subjects: 84
Study: 23673291

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride (HCl) extended release (ER) tablets (test formulation)
Number of subjects: 0
Study: 21146429

Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 31
Study: 19514189

Group type: EXPERIMENTAL
Intervention: Warming acupuncture group (needles warmed by burning moxa)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine group (Nimesulide tablets)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Point-injection group (Anisodamine injected)
Number of subjects: 90
Study: 17339748

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.33 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 15506597

Group type: EXPERIMENTAL
Intervention: Preoperative tests (routine medical tests and electrocardiograms)
Number of subjects: 1276

Group type: COMPARATOR
Intervention: No preoperative tests
Number of subjects: 1276
Study: 11678486

Group type: EXPERIMENTAL
Intervention: Workbook alone
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Computerized tailoring using onsite computer kiosks
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Both computers and staff consultation
Number of subjects: 588
Study: 9152195

Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscope (CCF)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal colonoscope (NCF)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection using transparent cap-fitted endoscope (EMRC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional strip biopsy
Number of subjects: 140
Study: 8432142

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3434997

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 100
Study: 28975353

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27458809

Group type: EXPERIMENTAL
Intervention: Supported telemonitoring intervention (self-measurement and transmission of glucose results to clinicians)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Supported telemonitoring intervention
Number of subjects: 321

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 321
Study: 24742587

Group type: EXPERIMENTAL
Intervention: HOPE programme (12-week exercise intervention)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 84
Study: 22044077

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 20838060

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg infused over 15 minutes every 3-4 weeks
Number of subjects: 14
Study: 18479280

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 17064504

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (ONCAB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pre-operative condition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Post-operative condition (3 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Post-operative condition (6 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Depressive group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Depression group characteristics
Number of subjects: 72